Castle Biosciences price to free cash flow CSTL

Market value divided by free cash flow over the last twelve months, since 2020.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 166×; Jul 2026
6-year median: 43.4×
6-year range: 10.1× to 347×
Peer median: 25.6×

Castle Biosciences' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Jul 2026, at 166×.

On the days it had one over the last 6 years, its median was 43.4×, from 10.1× in Aug 2025 to 347× in Apr 2021.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	166×	24.3×	166×
2025	45.3×	10.1×	46.0×
2024	21.8×	21.8×	45.7×
2023	n/m a value too high to mean anything
2022	n/m a value too high to mean anything
2021	295×	129×	347×
2020	130×	51.7×	173×

Against its peers

Companies in Medical - Diagnostics & Research nearest Castle Biosciences' size, closest first, today.

Company	Price to free cash flow
CSTLCastle Biosciences	n/m
NRCNRC Health	22.4×
CDNACareDx	n/m
VCYTVeracyte	23.2×
BLLNBillionToOne	153×
LNTHLantheus	16.8×
CAICaris Life Sciences	73.0×
BIOBio-Rad Laboratories	28.0×
Peer median	25.6×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Castle Biosciences

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.